Blog
EMA finds development challenges for medicines targeting CNS disorders in new report
The European Medicines Agency (EMA) released a report on Tuesday that analyzed over 100 applications submitted for medicines in the fields of psychiatry or neurology between 1995 and 2014. In the report, EMA concludes that various challenges can arise in the...
Experienced project manager joins Pearl Pathways
Pearl Pathways is pleased to announce the hiring of Shawn Knopp, PhD as an Advisor serving medical device and biopharmaceutical life science companies. Knopp brings to Pearl Pathways over 15 years of experience in multi-disciplinary life science roles including...
Advice from the experts: How to set up a successful community-based clinical trials program
Clinical research, when done correctly, provides a plethora of benefits to the researchers involved in the process as well as patients enrolled in the trials. Setting up a successful clinical trial process was the topic of a recent breakout session led by Daniel R....
FDA Issues Official Withdrawal of Proposed Rule Concerning Public Disclosure of Unapproved Gene Therapies
Two weeks ago, the US Food and Drug Administration (FDA) announced the withdrawal of a proposed rule from 2001. The rule would have required the public disclosure of summaries of safety and effectiveness data from pre-market clinical trials of gene therapies and...
Experienced quality analyst joins Pearl Pathways
Pearl Pathways is excited to announce the hiring of Phillip Bishop as a quality analyst. Bishop will help the Pearl team serve medical device and biopharmaceutical companies. Bishop brings 13 years of quality control (QC) laboratory experience to the Pearl Pathways...